Literature DB >> 3492513

Suppression of peripheral blood natural killer cell activity by excess thyroid hormone.

M Papic, J Stein-Streilein, M Zakarija, J M McKenzie, J Guffee, M A Fletcher.   

Abstract

Natural killer (NK) cells were assessed in patients with hyperthyroxinemia due to Graves' disease or treatment with thyroxine (T4). Cytolytic activity was measured with 51Cr-labeled K562 tumor cells and NK enumeration was by flow cytometry using NKH-1 monoclonal antibody to identify the relevant surface marker. Activity was uniformly decreased in association with hyperthyroxinemia, regardless of the underlying pathology; however, there was no reduction in the number of NKH-1+ cells. NK activity was enhanced by addition of interleukin 2 (IL-2) in both control and patients' cells although the value in the latter instance failed to reach the basal control level. Production of IL-2 by lymphocytes from hyperthyroxinemic subjects, in response to phytohemagglutinin, was also reduced. Since NK cells are thought to act as a defense against viral infections and some malignancies and may play a role in autoregulation of the immune system, this effect of T4 may have significant biological implications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492513      PMCID: PMC424085          DOI: 10.1172/JCI112826

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.

Authors:  L L Lanier; A M Le; C I Civin; M R Loken; J H Phillips
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

2.  Human fetal thymus and bone marrow contain target cells for natural killer cells.

Authors:  M Hansson; R Kiessling; B Andersson
Journal:  Eur J Immunol       Date:  1981-01       Impact factor: 5.532

3.  Peripheral K lymphocytes in autoimmune thyroid disease: decrease in Graves' disease and increase in Hashimoto's disease.

Authors:  N Amino; H Mori; Y Iwatani; S Asari; Y Izumiguchi; K Miyai
Journal:  J Clin Endocrinol Metab       Date:  1982-03       Impact factor: 5.958

4.  Quantitation of a whole blood assay for human natural killer cell activity.

Authors:  P C Ottenhof; A Morales; M G Baines
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

5.  T, B and K cells in autoimmune thyroid disease.

Authors:  E A Calder; W J Irvine; N M Davidson; F Wu
Journal:  Clin Exp Immunol       Date:  1976-07       Impact factor: 4.330

6.  Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

Authors:  H Rabin; R F Hopkins; F W Ruscetti; R H Neubauer; R L Brown; T G Kawakami
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

7.  Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients.

Authors:  P Hersey; A Hobbs; A Edwards; W H McCarthy; V J McGovern
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

8.  Clinical significance of assay of thyroid-stimulating antibody in Graves' disease.

Authors:  M Zakarija; J M McKenzie; K Banovac
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

9.  Cell-mediated cytotoxicity against virus-infected target cells in humans. I. Characterization of the effector lymphocyte.

Authors:  D Santoli; G Trinchieri; F S Lief
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

10.  Low natural-killer-cell activity in familial melanoma patients and their relatives.

Authors:  P Hersey; A Edwards; M Honeyman; W H McCarthy
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

View more
  10 in total

Review 1.  The role of NK cells in the autoimmune thyroid disease-associated pregnancy loss.

Authors:  Emiliana Konova
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

Review 2.  Natural killer cells and autoimmunity.

Authors:  E Grunebaum; E Malatzky-Goshen; Y Shoenfeld
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

3.  Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.

Authors:  F A Karlsson; T H Tötterman
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

4.  Modulation of the IL-2 production defect in vitro in Graves' disease.

Authors:  Z Eisenstein; E Engelsman; M Weiss; Y Kalechman; B Sredni
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

5.  Defective response of natural killer activity to thyroxine in Graves' disease.

Authors:  M S Lee; W S Hong; S W Hong; J O Lee; T W Kang
Journal:  Korean J Intern Med       Date:  1990-07       Impact factor: 2.884

Review 6.  Endobiogeny: a global approach to systems biology (part 2 of 2).

Authors:  Jean-Claude Lapraz; Kamyar M Hedayat; Patrice Pauly
Journal:  Glob Adv Health Med       Date:  2013-03

Review 7.  Natural Killer Cells and Thyroid Diseases.

Authors:  Eun Kyung Lee; John B Sunwoo
Journal:  Endocrinol Metab (Seoul)       Date:  2019-06

Review 8.  The interplay of thyroid hormones and the immune system - where we stand and why we need to know about it.

Authors:  Christina Wenzek; Anita Boelen; Astrid M Westendorf; Daniel R Engel; Lars C Moeller; Dagmar Führer
Journal:  Eur J Endocrinol       Date:  2022-03-23       Impact factor: 6.558

9.  Mass Cytometry Studies of Patients With Autoimmune Endocrine Diseases Reveal Distinct Disease-Specific Alterations in Immune Cell Subsets.

Authors:  Louise Magnusson; Hugo Barcenilla; Mikael Pihl; Sophie Bensing; Daniel Espes; Per-Ola Carlsson; Rosaura Casas
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

Review 10.  Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher.

Authors:  Daniela Gallo; Eliana Piantanida; Matteo Gallazzi; Luigi Bartalena; Maria Laura Tanda; Antonino Bruno; Lorenzo Mortara
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-17       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.